Combination therapies are a cost-effective alternative when treating visceral leishmaniasis

Combination therapies are a cost-effective alternative when treating visceral leishmaniasis

Visceral leishmaniasis is the second-deadliest parasitic disease after malaria. Each year, thousands fall victim among poor and marginalised populations in low-income countries. Filip Meheus is the first to detail the economic aspects of the disease in India, Nepal and Sudan. On Monday 16 September, Meheus will receive a PhD title at the University of Nijmegen for his research at the Institute of Tropical Medicine (ITM) in Antwerp.

Visceral leishmaniasis has become harder to control, because current treatments increasingly fail (like in Nepal with resistance to the drug miltefosine).

Meheus shows that combination therapies (the use of multiple drugs) is a cost-effective alternative to the current first-line treatments. This is mainly due to the shorter duration of treatment and the lower cost of the drugs used for combination therapies.

Combination therapies would also alleviate the enormous the disease causes in families and relieve the workload in hospitals. However, additional efforts are needed to further drop prices of some drugs (like liposomal amphotericin B) and diagnose and treat patients more quickly.

"This disease wrecks patients twice, both physically and financially. The study results offer some tools to assist them better, even where the needs are huge and the means limited," said Meheus.

The article is titled "The economic analysis of control."

More information: www.itg.be/internet/dl/Economi… trol-FilipMeheus.pdf

add to favorites email to friend print save as pdf

Related Stories

Kala-azar treatment failing in Nepal

Mar 01, 2013

In a recent study, scientists have concluded that the cure rates of Miltefosine, the only oral drug for visceral leishmaniasis available, have significantly decreased. Miltefosine was introduced in the Indian subcontinent ...

Old drug shows new promise to treat leishmaniasis

Feb 02, 2012

(Medical Xpress) -- A study published yesterday shows that a drug called fexinidazole could potentially be used to treat visceral leishmaniasis, a parasitic disease that kills 50 000 to 60 000 people ...

Genetics discovery to help fight 'black fever'

Jan 08, 2013

Scientists—including a geneticist at The University of Western Australia—are a step closer to developing a vaccine against a fatally infectious parasite carried in the bite of sandflies.

Recommended for you

Poll: Many doubt hospitals can handle Ebola

55 minutes ago

A new poll finds most Americans have some confidence that the U.S. health care system will prevent Ebola from spreading in this country, but they're not so sure their local hospital can safely handle a patient.

Number of Ebola cases nears 10,000

1 hour ago

The number of people with Ebola is set to hit 10,000 in West Africa, the World Health Organization said, as the scramble to find a cure gathered pace.

'Breath test' shows promise for diagnosing fungal pneumonia

1 hour ago

Many different microbes can cause pneumonia, and treatment may be delayed or off target if doctors cannot tell which bug is the culprit. A novel approach—analyzing a patient's breath for key chemical compounds made by the ...

Where Ebola battles are won

10 hours ago

(HealthDay)—Four hospitals that are home to advanced biocontainment facilities have become America's ground zero in the treatment of Ebola patients.

User comments